51 results about "Alcohol use disorder" patented technology

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.

Novel compounds such as DHMP maintain DHM features and pharmacological activities with increased potency and efficacy, improved water solubility, enhanced bioavailability, increased permeability to the blood brain barrier (BBB), and increased stability. Because DHMP retains the therapeutic activities of DHM and has properties that improve its bioavailability, it can be used as a therapeutic agent for treating Alzheimer's disease-related diseases (ADRD) including Alzheimer's disease (AD), Vascular Dementia, Frontotemporal Dementia (FTD), Mixed Dementia as well as neurodegeneration such as Parkinson's disease. Administration of these compounds result in beneficial pathological changes including reduction of Aꞵ and Tau, improvement of neuroinflammation, reduction of cognitive / memory deficits, as well as improvement of anxiety, depression, and aggression. The disclosed DHM derivatives can also be used to treat sleep disorders, neurological disorders such as PTSD, Autism, Epilepsy / Seizures, and Alcohol Use Disorders (AUD), fetal alcohol syndrome (FAD), substance addictions, and cancers.

According to the system for evaluating the treatment effect of the AUD patient through the electroencephalogram power spectrum characteristics, the electroencephalogram activity is captured through an electroencephalogram monitoring sensor, the electroencephalogram power spectrum characteristics in a resting state are calculated through a data processing unit, the electroencephalogram power spectrum characteristics are compared with a preset reference value or index modes in different psychological states, and the treatment effect of the AUD patient is evaluated. To identify features of brain activity of the patient. The preset value is based on a classification of subconsciousness and consciousness reactions of the AUD patient and statistically validated. The system judges the brain activity state and the treatment effect of the AUD patient according to the analysis result of the electroencephalogram power spectrum characteristics, and the analysis and judgment result is displayed through an output unit. The system can accurately evaluate the treatment effect of the new treatment method of subconsciousness memory degradation on the AUD patient, so as to provide accurate treatment and prevention strategies for the AUD patient.

A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.

According to the system for evaluating the treatment effect of the AUD patient through the electroencephalogram microscopic state indexes, the electroencephalogram activity is captured through the electroencephalogram monitoring sensor, the electroencephalogram microscopic state indexes in the resting state are calculated through the data processing unit, the electroencephalogram microscopic state indexes are compared with a preset reference value or index modes in different psychological states, and the treatment effect of the AUD patient is evaluated. To identify features of brain activity of the patient. The preset value is based on a classification of subconsciousness and consciousness reactions of the AUD patient and statistically validated. And the system judges the brain activity state and the treatment effect of the AUD patient according to the analysis result of the electroencephalogram microscopic state index, and displays the analysis and judgment result through an output unit. The system can accurately evaluate the treatment effect of the AUD patient so as to provide accurate treatment and prevention strategies for the AUD patient.

To provide a novel tetracycline derivative having reduced antimicrobial activity for use in treating disorders of the central nervous system.SOLUTION: Provided are novel molecules comprising a modified tetracycline molecule including Deamino Diacetyl Minocycline, Methyl Ether Minocycline, Ethyl Ether Minocycline, Propyl Ether Minocycline, Butyl Ether Minocycline, Butyl Ether Monoacetyl Minocycline, Butyl Ether Diacetyl Minocycline, Butyl Ether Triacetyl Minocycline, or Butyl Ether Tetra Acetyl Minocycline, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, and tautomers thereof, and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders.SELECTED DRAWING: None

Described herein are methods of treating alcohol use disorder in a subject in need thereof. The method including administering to the subject an effective amount of a composition including: Lactobacillus rhamnosus (LGG), Lactobacillus rhamnosus (LGG)-derived exosome-like nanoparticles (LDNPs), or any combination thereof. The Lactobacillus rhamnosus (LGG)-derived exosome-like nanoparticles (LDNPs) can include tryptophan metabolites.

The invention relates to application of an OIP5-AS1 gene in screening of alcohol use disorder, and belongs to the technical field of screening of alcohol use disorder. In order to solve the problem that an existing AUD screening method lacks a molecular marker related to genetic susceptibility and is difficult to realize early intervention and individualized prevention, the invention provides application of an OIP5-AS1 gene in alcohol use disorder screening, and particularly relates to application of the OIP5-AS1 gene in preparation of an alcohol use disorder screening kit. The OIP5-AS1 in a sample is amplified and detected through real-time fluorescent quantitative PCR (polymerase chain reaction) by taking plasma of a subject as a detection object, and if the relative expression quantity of the OIP5-AS1 gene reaches 1.53 threshold or above, the subject has genetic susceptibility to alcohol use disorder. The OIP5-AS1 gene as a marker can provide objective and quantifiable detection indexes, reflect individual genetic susceptibility and realize long-term risk prediction, and has important clinical application value.

The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure relates to methods of treating a subject having SUD who is at risk of relapse to alcohol use. In some embodiments, this disclosure relates to methods of promoting remission in a subject having SUD. In some embodiments, the SUD is alcohol use disorder (AUD), opioid use disorder (OUD), or a stimulant use disorder such as cocaine use disorder (CUD).

A method of treating opioid use disorder (OUD) or alcohol use disorder (AUD) includes administering a pharmaceutically effective amount of a topical composition comprising an anhydrous suspension including naltrexone to an oral cavity of a subject for oral absorption therein. The topical composition is formulated to self-emulsify in an aqueous environment of the oral cavity.

A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.

The invention discloses application of putrescine as a molecular marker in preparation of a reagent for evaluating the severity of alcohol use disorder. The reagent is used for detecting the content of putrescine in a sample. By detecting the putrescine content in the excrement sample of the tested person, the alcohol use disorder severity of the person can be evaluated, and the method has important clinical significance for formulating a better diagnosis and treatment scheme.

A combination therapy for use in treatment of substance abuse disorders, including alcohol use disorder (AUD) and opioid use disorder (OUD), includes both mitragynine (MG) and naltrexone (NTX). NTX is understood to be a mu opioid antagonist that is expected to block MG's analgesic effects. However, combining MG and NTX therefore results in a unique, unexpected, and beneficial treatment that decreases alcohol self-administration to a greater extent than either alone.

Disclosed herein are compositions and methods for treating opioid use disorders, including opioid overdose with combinations including methocinnamox and at least one additional opioid modulators, for example opioid agonists, partial agonists, antagonists and allosteric modulators. The compositions and methods are also useful for treating alcohol use disorder, and other disorders associated with endogenous opioid production.

The invention discloses a prediction model for identifying alcohol use disorder and alcoholic hepatitis and application, a multi-dimensional identification model is constructed by integrating basic clinical information of a patient, intestinal bacterial community characteristics and an intestinal fungal flora structure, and the model is used for identifying alcohol use disorder and alcoholic hepatitis by means of conjoint analysis of intestinal micro-ecological flora (bacteria and fungi) and patient baseline data. A molecular marker combination scheme with innovativeness and practicability is provided for accurate differential diagnosis of AUD and AH.

The present disclosure provides novel 4-substituted-phenyl acetamide and arylurea derivatives that act as agonists against GPR88. The compounds of the present disclosure are believed to be useful for the treatment of diseases and conditions caused by physiological processes implicating the orphan receptor GPR88, including diverse brain and behavioral functions such as cognition, mood, movement control, and reward-based learning. GPR88 is emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction. One particular indication for which GPR88 agonists hold promise is alcohol use disorder (AUD).

Disclosed are method for predicting naltrexone response in subjects with AUD. In some embodiments, the methods include performing or having performed one or more methylation assays on a genomic DNA sample isolated from the subject to determine the methylation status of one or more regions of the isolated genomic DNA, wherein the one or more regions are subsequences of a gene selected from a mu opioid receptor (OPRM1) gene, a catechol-O-methyltransferase (COMT) gene, and a dopamine transporter (SLC6A3) gene, wherein the methylation status of the one or more regions of the isolated genomic DNA determined is predictive of naltrexone response in the subject. Also provided are method for treating patients diagnosed with AUD with the medication naltrexone based on a methylation status of a combination of specific methylation sites located associated with an OPRM1 gene, a COMT gene, and / or an SLC6A3 gene in obtained from each AUD patient.

The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.

Provided is an analytical method for providing information necessary for a diagnosis of alcohol use disorder, including measuring (i) an expression level of a gene encoding a JNK or p-JNK protein in a subject's sample, (ii) an expression level of a gene encoding a JNK or p-JNK protein and an expression level of a gene encoding the Elk-1 protein in a subject's sample, or (iii) expression levels of genes encoding JNK, p-JNK, and Elk-1 proteins in a subject's sample, respectively; and a kit for a diagnosis of alcohol use disorder which is used in the analytical method.

The present disclosure provides novel 4-substituted phenylacetamide and aryl urea derivatives that act as agonists for GPR88.The compounds of the present disclosure are believed to be useful for treating diseases and conditions caused by physiological processes that involve the orphan receptor GPR88, including diverse brain and behavioral functions such as cognition, mood, motor control, and reward-based learning.GPR88 has emerged as a novel drug target for central nervous system disorders, including schizophrenia, Parkinson's disease, anxiety, and addiction.One particular indication for which GPR88 agonists are promising is alcohol use disorder (AUD).

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.

The invention provides a system for evaluating the treatment effect of a patient suffering from alcohol use disorder by utilizing EEG indexes. The system utilizes EEG indexes to monitor and analyze physiological and neural responses of the patient. The system measures electroencephalogram activity through an electroencephalogram monitoring sensor, then calculates a nonlinear kinetic index of the EEG through a data processing unit, and compares the nonlinear kinetic index of the EEG with a preset reference value or index mode to identify the psychological state and physiological response characteristics of the patient. Finally, the system judges the physiological state, the brain activity state and the treatment effect of the alcohol use disorder patient according to the analysis result of the EEG indexes, and the analysis and judgment result is displayed through an output unit. The system can accurately evaluate the treatment effect of the patient with the alcohol use disorder, so that accurate treatment and prevention strategies are provided for the patient with the alcohol use disorder.

This invention discloses a predictive model and its application for differentiating between alcohol use disorder (AUD) and alcoholic hepatitis (AH). By integrating the patient's basic clinical information, gut bacterial community characteristics, and gut fungal community structure, a multi-dimensional differentiation model is constructed. This model, through the joint analysis of gut microbiota (bacteria + fungi) and patient baseline data, provides an innovative and practical combination of molecular markers for the accurate differential diagnosis of AUD and AH.

Novel compounds such as DHMP maintain DHM features and pharmacological activities with increased potency and efficacy, improved water solubility, enhanced bioavailability, increased permeability to the blood brain barrier (BBB), and increased stability. Because DHMP retains the therapeutic activities of DHM and has properties that improve its bioavailability, it can be used as a therapeutic agent for treating Alzheimer's disease-related diseases (ADRD) including Alzheimer's disease (AD), Vascular Dementia, Frontotemporal Dementia (FTD), Mixed Dementia as well as neurodegeneration such as Parkinson's disease. Administration of these compounds result in beneficial pathological changes including reduction of Aꞵ and Tau, improvement of neuroinflammation, reduction of cognitive / memory deficits, as well as improvement of anxiety, depression, and aggression. The disclosed DHM derivatives can also be used to treat sleep disorders, neurological disorders such as PTSD, Autism, Epilepsy / Seizures, and Alcohol Use Disorders (AUD), fetal alcohol syndrome (FAD), substance addictions, and cancers.

Provided herein are methods of treating alcohol use disorder (AUD), opioid use disorder (OUD), and other substance use disorders (SUDs) in a subject, for example by administering an oral transmucosal dosage form of esketamine, such as an oral thin film (OTF) form of esketamine, sublingually or buccally. Disclosed methods may combine one or more therapy modalities provided before, during, and / or after drug administration. In some aspects, the methods comprise administering a dose of esketamine that is sufficient to produce dissociative effects in a subject. In some further aspects, the methods comprise the use of specific therapy modalities or ketamine-assisted psychotherapy (KAP) protocols, including manualized relapse prevention cognitive behavioral therapy (CBT). In yet further aspects, the methods comprise ongoing support, including additional psychotherapy and / or adjunct medication, such as naltrexone, buprenorphine, buprenorphine-naloxone, disulfiram, naloxone, and others.

A composition for use in a method of treating Alcohol Use Disorder (AUD), tobacco use, pain, or proinflammatory disorders comprising: an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula: wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.

The present disclosure relates to methods for treating a subject having a substance use disorder (SUD) with a 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulator. Specifically, in some embodiments, the present disclosure relates to methods for treating a subject having SUD at risk of relapse to alcohol use. In some embodiments, the present disclosure relates to methods for promoting remission in a subject having SUD. In some embodiments, the SUD is a stimulant use disorder such as alcohol use disorder (AUD), opioid use disorder (OUD), or cocaine use disorder (CUD).

The present invention relates to the use of macvalerian or a pharmaceutically acceptable salt thereof in reducing the use of alcohol in patients with alcohol use disorder; application in preventing alcohol reuse of a patient with alcohol use disorder; application in promoting alcohol abstinence of a patient with alcohol use disorder; use in the treatment of depression or anxiety symptoms associated with alcohol use disorders.